Get the Stockscreener App
6.82
2.40%
0.16
After Hours:
6.80
-0.02
-0.29%
Aquestive Therapeutics Inc stock is traded at $6.82, with a volume of 1.74M.
It is up +2.40% in the last 24 hours and up +22.00% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$6.66
Open:
$6.68
24h Volume:
1.74M
Relative Volume:
0.63
Market Cap:
$680.12M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-18.73
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-0.29%
1M Performance:
+22.00%
6M Performance:
+133.16%
1Y Performance:
+24.23%
1-Day Range:
$6.575
$6.87
1-Week Range:
$6.39
$7.0844
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
6.82 | 805.68M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Can Aquestive's Oral, Non-Device Epinephrine Film Capture A Share Of The Growing U.S. Market? - RTTNews
Will Aquestive Therapeutics Inc. bounce back from current supportWeekly Profit Recap & Consistent Growth Equity Picks - newser.com
Detecting support and resistance levels for Aquestive Therapeutics Inc.Weekly Trade Review & Weekly Watchlist for Hot Stocks - newser.com
Why Aquestive Therapeutics Inc. stock could outperform in 2025July 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Real time alert setup for Aquestive Therapeutics Inc. performanceJuly 2025 Short Interest & AI Driven Stock Reports - newser.com
Volatility clustering patterns for Aquestive Therapeutics Inc.Share Buyback & High Accuracy Trade Alerts - newser.com
Will Aquestive Therapeutics Inc. stock gain from strong economyJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Can technical indicators confirm Aquestive Therapeutics Inc.’s reversalChart Signals & Stepwise Swing Trade Plans - newser.com
Long term hold vs stop loss in Aquestive Therapeutics Inc.Quarterly Profit Review & Detailed Earnings Play Alerts - newser.com
Why Aquestive Therapeutics Inc. stock is trending among retail tradersProduct Launch & Low Risk Investment Opportunities - newser.com
Risk vs reward if holding onto Aquestive Therapeutics Inc.2025 Volatility Report & Smart Money Movement Alerts - newser.com
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting - The Manila Times
Aquestive Therapeutics Inc. stock chart pattern explainedMarket Risk Report & Real-Time Market Trend Scan - newser.com
Using AI based signals to follow Aquestive Therapeutics Inc.2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
What Wall Street predicts for Aquestive Therapeutics Inc. stock priceGDP Growth & Safe Entry Trade Reports - newser.com
Top chart patterns to watch in Aquestive Therapeutics Inc.July 2025 Macro Moves & Low Risk High Win Rate Stock Picks - newser.com
Is Aquestive Therapeutics Inc. stock attractive for retirement portfoliosWeekly Trade Summary & Accurate Entry and Exit Point Alerts - newser.com
Will Aquestive Therapeutics Inc. stock benefit from AI adoptionCPI Data & Safe Swing Trade Setup Alerts - Fundação Cultural do Pará
Can trapped investors hope for a rebound in Aquestive Therapeutics Inc.Dividend Hike & High Accuracy Investment Signals - newser.com
Why Aquestive Therapeutics Inc. stock attracts high net worth investors - Fundação Cultural do Pará
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics to Report Third Quarter 2025 - GlobeNewswire
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - MarketBeat
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Sale |
7.01 |
67,575 |
473,701 |
240,771 |
| Kraus Carl N | Chief Medical Officer |
Oct 15 '25 |
Sale |
7.00 |
20,272 |
141,904 |
282,475 |
| Boyd Peter E. | See Remarks |
Oct 15 '25 |
Sale |
7.00 |
10,000 |
70,000 |
268,323 |
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):